SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer-Reference-Cited by-同舟云学术

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Published:2015-11 Issue:5 Volume:68 Page:837-847
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Eichelberg Christian,Vervenne Walter L.,De Santis Maria,Fischer von Weikersthal Ludwig,Goebell Peter J.,Lerchenmüller Christian,Zimmermann Uwe,Bos Monique M.E.M.,Freier Werner,Schirrmacher-Memmel Silke,Staehler Michael,Pahernik Sascha,Los Maartje,Schenck Marcus,Flörcken Anne,van Arkel Cornelis,Hauswald Kirsten,Indorf Martin,Gottstein Dana,Michel Maurice S.

Publisher

Elsevier BV

Subject

Urology

Reference44 articles.

1. Evolving therapeutic targets in renal cell carcinoma;Singer;Curr Opin Oncol,2013

2. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial;Motzer;Lancet Oncol,2014

3. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement;Porta;Med Oncol,2012

4. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit;Oudard;Cancer Treat Rev,2012

5. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Cancer Res,2003

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass);European Urology;2023-12

2. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-09-07

3. Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System;BMC Cancer;2023-05-30

4. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis;Cochrane Database of Systematic Reviews;2023-05-04

5. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021;Journal of Hematology & Oncology;2022-10-08